New immunotherapy combination tolerable, effective in patients with advanced kidney cancer
(Georgetown University Medical Center) Combining an anti-angiogenesis agent, which blocks blood vessel formation, with an immunotherapy agent, was found to have promising anti-tumor activity and no unexpected side effects in an early-phase clinical trial in patients with advanced kidney cancer.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Clinical Trials | Immunotherapy | Kidney Cancer | Urology & Nephrology